Sirolimus does not increase the risk for postoperative thromboembolic events among renal transplant recipients

Transplantation

Volumn 76, Issue 2, 2003, Pages 318-323

  Langer, Robert M ^a,b   Kahan, Barry D ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN A; PREDNISONE; RAPAMYCIN;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DISEASE PREDISPOSITION; FEMALE; FISHER EXACT TEST; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; KIDNEY VEIN THROMBOSIS; LUNG EMBOLISM; LYMPHOCELE; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RENAL ARTERY THROMBOSIS; RISK ASSESSMENT; THROMBOEMBOLISM;

ADULT; ANTI-INFLAMMATORY AGENTS; COHORT STUDIES; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY; KIDNEY TRANSPLANTATION; LYMPHOCELE; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREDNISONE; RETROSPECTIVE STUDIES; RISK FACTORS; SIROLIMUS; THROMBOEMBOLISM;

EID: 0043269247     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000071203.62964.DA     Document Type: Article

References (26)

1. Persson AV, Davis RJ, Villavicencio JL. Deep venous thrombosis and pulmonary embolism. Surg Clin North Am 1991; 71: 1195.
2. Cherney DZ, Zaltzman JS. Mycophenolate mofetil causing deep venous thrombosis in a renal transplant patient with factor V Leiden. Nephrol Dial Transplant 2001; 16: 1702.
3. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222.
4. Irish AB, Green FR, Gray DW, et al. The factor V Leiden (R506Q) mutation and risk of thrombosis in renal transplant recipients. Transplantation 1997; 64: 604.
5. Tveit DP, Hypolite IO, Hshieh P, et al. Chronic dialysis patients have high risk for pulmonary embolism. Am J Kidney Dis 2002; 39: 1011.
6. Bergqvist D, Bergentz SE, Bornmyr S, et al. Deep vein thrombosis after renal transplantation: a prospective analysis of frequency and risk factors. Eur Surg Res 1985; 17: 69.
7. Rao KV, Smith EJ, Alexander JW, et al. Thromboembolic disease in renal allograft recipients. What is its clinical significance? Arch Surg 1976; 111: 1086.
8. Allen RD, Michie CA, Murie JA, et al. Deep venous thrombosis after renal transplantation. Surg Gynecol Obstet 1987; 164: 137.
9. Brunkwall J, Bergqvist D, Bergentz SE, et al. Postoperative deep venous thrombosis after renal transplantation. Effects of cyclosporine. Transplantation 1987; 43: 647.
10. Ducloux D, Pellet E, Fournier V, et al. Prevalence and clinical significance of antiphospholipid antibodies in renal transplant recipients. Transplantation 1999; 67: 90.
11. Schwieger J, Reiss R, Cohen JL, et al. Acute renal allograft dysfunction in the setting of deep venous thrombosis: a case of successful urokinase thrombolysis and a review of the literature. Am J Kidney Dis 1993; 22: 345.
12. Arnadottir M, Bergentz SE, Bergquist D, et al. Thromboembolic complications after renal transplantation: a retrospective analysis. World J Surg 1983; 7: 757.
13. Vachharajani TJ, Asari AJ, Tucker B, et al. Ipsilateral deep venous thrombosis in renal transplant recipients: the need for prolonged anticoagulation. Nephrol Dial Transplant 1997; 12: 627.
14. Humar A, Johnson EM, Gillingham KJ, et al. Venous thromboembolic complications after kidney and kidney-pancreas transplantation: a multivariate analysis. Transplantation 1998; 65: 229.
15. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725.
16. Merion RM, White DJ, Thiru S, et al. Cyclosporine: five years' experience in cadaveric renal transplantation. N Engl J Med 1984; 310: 148.
17. Vanrenterghem Y, Roels L, Lerut T, et al. Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients. Lancet 1985; 1: 999.
18. Babinska A, Markell MS, Salifu MO, et al. Enhancement of human platelet aggregation and secretion induced by rapamycin. Nephrol Dial Transplant 1998; 13: 3153.
19. Amante AJ, Kahan BD. Abbreviated area-under-the-curve strategy for monitoring cyclosporine microemulsion therapy in immediate posttransplant period. Clin Chem 1996; 42: 1294.
20. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
21. Tveit DP, Hypolite I, Bucci J, et al. Risk factors for hospitalizations resulting from pulmonary embolism after renal transplantation in the United States. J Nephrol 2001; 14: 361.
22. Kahan BD, for the Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 2000; 356: 194.
23. Merkus JW, Barendregt WB, van Asten WN, et al. Changes in venous hemodynamics after renal transplantation. Transpl Int 1998; 11: 284.
24. Podder H, Stepkowski SM, Napoli KL, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 2001; 12: 1059.
25. Taillefer R, Edell S, Innes G, et al. Acute thromboscintigraphy with (99m)Tc-apcitide: results of the phase 3 multicenter clinical trial comparing 99mTc-apcitide scintigraphy with contrast venography for imaging acute DVT. Multicenter Trial Investigators. J Nucl Med 2000; 41: 1214.
26. Langer RM, Kahan BD. Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients. Transplantation 2002; 74: 804.